WO2025185732 - RIPK1 INHIBITOR AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/185732
Publication Date
11.09.2025
International Application No.
PCT/CN2025/081276
International Filing Date
07.03.2025
Title **
[English]
RIPK1 INHIBITOR AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
[French]
INHIBITEUR DE RIPK1 ET SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION PHARMACEUTIQUE
[Chinese]
RIPK1抑制剂、其制备方法及其在医药上的应用
Applicants **
SHANDONG QUANZHONG BIOMEDICAL TECHNOLOGY CO., LTD.
Inventors
TIAN, Jingwei
YE, Liang
YANG, Yifei
SONG, Ziwei
ZHANG, Jianzhao
LU, Jing
WANG, Wenyan
Priority Data
202410264157.9
08.03.2024
CN
202411099909.7
12.08.2024
CN
202411721855.3
28.11.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2127 | |
| EPO | Filing, Examination, Granting | 13172 | |
| Japan | Filing, Examination, Granting | 2037 | |
| South Korea | Filing, Examination, Granting | 1924 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
24,000
Contact Us
Abstract[English]
The present invention relates to a novel compound for inhibiting receptor interacting protein kinase 1 (RIPK1), and a use thereof in the preparation of drugs for treating or preventing RIPK1-mediated diseases. Specifically, the present invention relates to a compound represented by the general formula or a tautomer thereof, or a pharmaceutically acceptable composition comprising same.[French]
La présente invention concerne un nouveau composé pour inhiber la protéine kinase 1 interagissant avec le récepteur (RIPK1), et son utilisation dans la préparation de médicaments pour le traitement ou la prévention de maladies médiées par RIPK1. Plus particulièrement, la présente invention concerne un composé représenté par la formule générale ou un tautomère de celui-ci, ou une composition pharmaceutiquement acceptable le comprenant.[Chinese]
本发明涉及抑制受体相互作用蛋白激酶1(RIPK1)的新型化合物，及其在制备治疗或预防RIPK1介导的疾病的药物中的应用。具体涉及通式所示化合物、其互变异构体或其药学上可接受的组合物。